Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steve Knapper

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Hematology. American Society of Hematology. Education Program|November 21, 2007
Targeting treatment in AMLAlan K Burnett, Steve Knapper
Frontiers in Oncology|June 16, 2022
Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug EffluxRachael Nicholson, Ana Catarina Menezes, Aleksandra Azevedo, et al.
British Journal of Haematology|May 13, 2020
Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemiaJoanna Zabkiewicz, Michelle Lazenby, Gareth Edwards, et al.
Haematologica|July 7, 2018
Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trialAlan K Burnett, Emma Das Gupta, Steve Knapper, et al.
Plos One|September 27, 2016
Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid LeukemiaNaeem Khan, Robert K Hills, Steve Knapper, et al.
BMC Cancer|November 15, 2022
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trialRichard Dillon, Shanna Maycock, Aimee Jackson, et al.
The Lancet. Oncology|September 19, 2015
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trialAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
British Journal of Haematology|December 27, 2021
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemiaThomas Coats, Daniel Bean, Aymeric Basset, et al.
Leukemia|December 26, 2022
Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemiaNamrata Rastogi, Juan Bautista Menendez Gonzalez, Vikas Kumar Srivastava, et al.
Blood Advances|May 12, 2023
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trialJad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Hematology. American Society of Hematology. Education Program|November 21, 2007
Targeting treatment in AMLAlan K Burnett, Steve Knapper
Frontiers in Oncology|June 16, 2022
Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug EffluxRachael Nicholson, Ana Catarina Menezes, Aleksandra Azevedo, et al.
British Journal of Haematology|May 13, 2020
Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemiaJoanna Zabkiewicz, Michelle Lazenby, Gareth Edwards, et al.
Haematologica|July 7, 2018
Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trialAlan K Burnett, Emma Das Gupta, Steve Knapper, et al.
Plos One|September 27, 2016
Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid LeukemiaNaeem Khan, Robert K Hills, Steve Knapper, et al.
BMC Cancer|November 15, 2022
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trialRichard Dillon, Shanna Maycock, Aimee Jackson, et al.
The Lancet. Oncology|September 19, 2015
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trialAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
British Journal of Haematology|December 27, 2021
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemiaThomas Coats, Daniel Bean, Aymeric Basset, et al.
Leukemia|December 26, 2022
Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemiaNamrata Rastogi, Juan Bautista Menendez Gonzalez, Vikas Kumar Srivastava, et al.
Blood Advances|May 12, 2023
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trialJad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, et al.
Pageof 2